Aggressive pulmonary adenocarcinoma with new FGFR translocation and cMET mutation not responsive to crizotinib and nintedanib treatment: a case report

por Svaton, Martin, Vanecek, Tomas, Mukensnabl, Petr, Baxa, Jan, Krakorova, Gabriela, Blazek, Jiri, Pesek, Milos
Publicado 2020

Acute Mediastinitis – Outcomes and Prognostic Factors of Surgical Therapy (A Single-Center Experience)

por Vodicˇka, Josef, Geiger, Jan, Židková, Alexandra, Andrle, Pavel, Mírka, Hynek, Svatonˇ, Martin, Kostlivý, Tomáš
Publicado 2022

Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib

por Svaton, Martin, Fiala, Ondrej, Krakorova, Gabriela, Blazek, Jiri, Hurdalkova, Karolina, Barinova, Magda, Mukensnabl, Petr, Pesek, Milos
Publicado 2020

Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capilla...

por Benesova, Lucie, Ptackova, Renata, Halkova, Tereza, Semyakina, Anastasiya, Svaton, Martin, Fiala, Ondrej, Pesek, Milos, Minarik, Marek
Publicado 2022

Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer

por Pesta, Martin, Shetti, Dattatrya, Kulda, Vlastimil, Knizkova, Tereza, Houfkova, Katerina, Bagheri, Mahyar Sharif, Svaton, Martin, Polivka, Jiri
Publicado 2022

Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy

por Svaton, Martin, Blazek, Jiri, Krakorova, Gabriela, Buresova, Marcela, Teufelova, Zuzana, Vodicka, Josef, Hurdalkova, Karolina, Barinova, Magda, Pesek, Milos
Publicado 2021

Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC

por Buresova, Marcela, Benesova, Lucie, Minarik, Marek, Ptackova, Renata, Halkova, Tereza, Hosek, Petr, Baxa, Jan, Pesek, Milos, Svaton, Martin, Fiala, Ondrej
Publicado 2023

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

por Bratova, Monika, Skrickova, Jana, Matusikova, Magda, Hrabcova, Karolina, Havel, Libor, Koubkova, Leona, Hrnciarik, Michal, Krejci, Jana, Fischer, Ondrej, Svaton, Martin, Brat, Kristian
Publicado 2023

Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer

por Svaton, Martin, Drosslerova, Marie, Fischer, Ondrej, Marel, Miloslav, Hrnciarik, Michal, Venclicek, Ondrej, Zuna, Petr, Svoboda, Michal, Blazek, Jiri, Bratova, Monika, Mullerova, Andrea, Vankova, Bohuslava, Krejci, Daniel
Publicado 2022

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

por Brat, Kristian, Bratova, Monika, Skrickova, Jana, Barinova, Magda, Hurdalkova, Karolina, Pesek, Milos, Havel, Libor, Koubkova, Leona, Hrnciarik, Michal, Krejci, Jana, Fischer, Ondrej, Zemanova, Milada, Coupkova, Helena, Svaton, Martin
Publicado 2020